Search

Your search keyword '"Christy Chao"' showing total 2 results
Start Over Author "Christy Chao" Topic blood glucose self-monitoring
2 results on '"Christy Chao"'

1. Assessing non‐adjunctive CGM safety at home and in new markets (ANSHIN)

Author

Christy Chao, Sarah B. Andrade, Simon Bergford, Peter Calhoun, John B. Welsh, Tomas C. Walker, and ANSHIN Study Group

Subjects
blood glucose self‐monitoring, glycated haemoglobin, glycaemic control, Diseases of the endocrine glands. Clinical endocrinology, RC648-665
Abstract

Abstract Introduction Continuous glucose monitoring (CGM) can guide treatment for people with type 1 (T1D) and type 2 diabetes (T2D). The ANSHIN study assessed the impact of non‐adjunctive CGM use in adults with diabetes using intensive insulin therapy (IIT). Materials and Methods This single‐arm, prospective, interventional study enrolled adults with T1D or T2D who had not used CGM in the prior 6 months. Participants wore blinded CGMs (Dexcom G6) during a 20‐day run‐in phase, with treatment based on fingerstick glucose values, followed by a 16‐week intervention phase and then a randomized 12‐week extension phase with treatment based on CGM values. The primary outcome was change in HbA1c. Secondary outcomes were CGM metrics. Safety endpoints were the number of severe hypoglycaemic (SH) and diabetic ketoacidosis (DKA) events. Results Of the 77 adults enrolled, 63 completed the study. Those enrolled had mean (SD) baseline HbA1c of 9.8% (1.9%), 36% had T1D, and 44% were ≥65 years old. Mean HbA1c decreased by 1.3, 1.0 and 1.0 percentage points for participants with T1D, T2D or age ≥65, respectively (p

Published
2023
Full Text
View/download PDF

2. With or Without Residual C-Peptide, Patients with Type 2 Diabetes Realize Glycemic Benefits from Real-Time Continuous Glucose Monitoring

Author

Tomas C. Walker, Peter Calhoun, Ryan R. Bailey, and Christy Chao

Subjects
Adult, Blood Glucose, medicine.medical_specialty, endocrine system diseases, Endocrinology, Diabetes and Metabolism, medicine.medical_treatment, Type 2 diabetes, Gastroenterology, chemistry.chemical_compound, Endocrinology, Diabetes mellitus, Internal medicine, medicine, Humans, Hypoglycemic Agents, Insulin, Glycemic, Glycated Hemoglobin, Blood glucose monitoring, C-Peptide, medicine.diagnostic_test, Continuous glucose monitoring, business.industry, C-peptide, Blood Glucose Self-Monitoring, Basal insulin, nutritional and metabolic diseases, medicine.disease, Medical Laboratory Technology, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, chemistry, Disease Progression, business
Abstract

Real-time continuous glucose monitoring (RT-CGM) is superior to blood glucose monitoring (BGM) for adults with insulin-treated type 2 diabetes (T2D); however, the utility of C-peptide levels for predicting the magnitude of the glycemic benefits is controversial. Data were from a subset of 147 participants in the MOBILE study (NCT03566693) who were treated with basal-only insulin and who had baseline C-peptide levels ≥0.5 ng/mL. Participants were randomized to treatment with either RT-CGM (n=100) or BGM (n=47). Between-group differences in HbA1c and time in range (TIR) changes were assessed. The between-group difference in HbA1c favored the RT-CGM group (by 0.58 percentage points, P=0.004 at 3 months and by 0.42 percentage points, P=0.04 at 8 months). TIR was 16% higher, and time >180 mg/dL was 16% lower, in the RT-CGM group at 8 months (P=0.002 for each). In T2D managed with basal insulin, RT-CGM benefits occur for those with residual insulin secretory capacity.

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results